

Serum Insulin-Like Growth Factor 1 and the Risk of Ischemic Stroke

The Framingham Study

Hamidreza Saber, MD, MPH; Jayandra J. Himali, PhD; Alexa S. Beiser, PhD; Ashkan Shoamanesh, MD; Aleksandra Pikula, MD; Ronenn Roubenoff, MD; Jose R. Romero, MD; Carlos S. Kase, MD; Ramachandran S. Vasan, MD; Sudha Seshadri, MD

Background and Purpose—Low insulin-like growth factor 1 (IGF-1) has been associated with increased risk of atherosclerosis and atrial fibrillation in cross-sectional studies. Yet, prospective data linking IGF-1 levels to the development of ischemic stroke remain inconclusive. We examined prospectively the association between serum IGF-1 levels and incident ischemic stroke.

Methods—We measured serum IGF-1 levels in 757 elderly individuals (mean age 79±5, 62% women), free of prevalent stroke, from the Framingham original cohort participants at the 22nd examination cycle (1990–1994) and were followed up for the development of ischemic stroke. Cox models were used to relate IGF-1 levels to the risk for incident ischemic stroke, adjusted for potential confounders.

Results—During a mean follow-up of 10.2 years, 99 individuals developed ischemic stroke. After adjustment for age, sex, and potential confounders, higher IGF-1 levels were associated with a lower risk of incident ischemic stroke, with subjects in the lowest quintile of IGF-1 levels having a 2.3-fold higher risk of incident ischemic stroke (95% confidence interval, 1.09–5.06; $P=0.03$) as compared with those in the top quintile. We observed an effect modification by diabetes mellitus and waist–hip ratio for the association between IGF-1 and ischemic stroke ($P<0.1$). In subgroup analyses, the effects were restricted to subjects with diabetics and those in top waist–hip ratio quartile, in whom each standard deviation increase in IGF-1 was associated with a 61% (hazard ratio, 0.39; 95% confidence interval, 0.20–0.78; $P=0.007$) and 41% (hazard ratio, 0.59; 95% confidence interval, 0.37–0.95; $P=0.031$) lower risk of incident ischemic stroke, respectively.

Conclusions—IGF-1 levels were inversely associated with ischemic stroke, especially among persons with insulin resistance. (*Stroke*. 2017;48:1760–1765. DOI: 10.1161/STROKEAHA.116.016563.)

Key Words: atrial fibrillation ■ IGF-1 ■ insulin resistance ■ ischemic stroke ■ risk

Recent experimental and clinical studies indicate physiological benefits of insulin-like growth factor-1 (IGF-1) on vascular functions. In recent basic science studies, IGF-1 has been shown to reduce atherosclerosis burden through antiapoptotic¹ and anti-inflammatory² properties and protect vascular function by promoting nitric oxide (NO) production from the endothelium and vascular smooth muscle cells.³ IGF-1 also enhances insulin sensitivity⁴ and induces vasodilation,⁵ thereby, regulating glucose homeostasis, blood pressure, and cerebral blood flow.^{6,7} Additionally, low circulating IGF-1 levels have been associated with increased carotid intima-media thickness⁸ and atrial fibrillation⁹ in an elderly population. Lower levels of IGF-1 have been found to be associated

with the presence of traditional vascular risk factors, particularly obesity,¹⁰ insulin resistance, and diabetes mellitus.^{4,11} Hence, the effects of IGF-1 levels on vascular events may also be mediated through pathways of insulin resistance.

The association of IGF-1 with the risk of incident ischemic stroke, however, remains unclear. Two previous prospective observational studies that have examined this association were inconsistent, with one study showing a protective role for IGF-1 and another study showing no association with incident ischemic stroke.^{12,13} On the other hand, higher IGF-1 levels have been associated with early carotid artery atherosclerosis.¹⁴ While it has been shown that the physiological effects of IGF-1 on vasculature may be altered in persons with insulin

Received December 30, 2016; final revision received April 4, 2017; accepted May 4, 2017.

From the Framingham Heart Study, MA (H.S., J.J.H., A.S.B., J.R.R., C.S.K., R.S.V., S.S.); Boston University School of Public Health, MA (J.J.H., A.S.B.); McMaster University/Population Health Research Institute, Hamilton, Ontario, Canada (A.S.); Department of Neurology, University of Toronto, Ontario, Canada (A.P.); Department of Medicine, Tufts University School of Medicine, Boston, MA (R.R.); Department of Neurology, Boston University School of Medicine, MA (J.J.H., A.S.B., J.R.R., C.S.K., R.S.V., S.S.); and Department of Neurology, Wayne State University School of Medicine, Detroit, MI (H.S.).

The online-only Data Supplement is available with this article at <http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.116.016563/-/DC1>.

Correspondence to Sudha Seshadri, MD, Department of Neurology, Boston University School of Medicine, 72 E Concord St, Boston, MA 02118. E-mail suseshad@bu.edu

© 2017 American Heart Association, Inc.

Stroke is available at <http://stroke.ahajournals.org>

DOI: 10.1161/STROKEAHA.116.016563

resistance, no previous study has examined this association in insulin-resistant states.

To clarify these gaps in knowledge, we prospectively related circulating IGF-1 levels to the risk of ischemic stroke in a large, community-based cohort of elderly individuals. We hypothesized that higher circulating IGF-1 levels would be associated with a lower risk of ischemic stroke, particularly in insulin-resistant states.

Methods

The design and selection criteria of the Framingham Heart Study original cohort have been described elsewhere.¹⁵ Briefly, between 1948 and 1953, a total of 5209 participants were recruited and have been examined approximately every 2 years. IGF-1 levels were measured in 796 participants from generation 1 of a total of 1116 people who attended the 22nd examination cycle (1990–1994). The remaining people did not have sufficient serum drawn to permit IGF-1 assay. Thirty-nine participants were excluded for prevalent stroke (Figure I in the [online-only Data Supplement](#)). The study protocol was approved by the Institutional Review Board of the Boston University Medical Center, and all participants provided written informed consent prior to assessments.

Measurement of Serum IGF-1

At the baseline examination, 3 mL of serum from each participant was obtained from subjects in a supine, nonfasting state in the afternoon and stored at -80°C . Serum IGF-1 was measured by radioimmunoassay after acid-ethanol extraction in 3 batches¹⁶; the intra-assay coefficient of variation was $<4\%$. Insulin-like growth factor binding protein levels were not measured.

End Points

All Framingham Study participants are under continuous surveillance for stroke. We have previously outlined our screening and surveillance methods for the development of stroke.¹⁷ In brief, stroke was defined as an acute-onset focal neurological deficit of presumed vascular pathogenesis lasting ≥ 24 hours. Ischemic stroke was diagnosed if a focal neurological deficit was documented in the presence of a normal computed tomography scan, computed tomography or magnetic resonance imaging showed an infarct that correlated with the clinical deficit, or an infarct was documented at autopsy. Using this information, it was possible to classify stroke subtypes as large-vessel atherothrombotic and lacunar infarction and cardioembolic from a documented cardiac source.

Statistical Analysis

Serum IGF-1 levels were standardized within sex. Multivariable-adjusted Cox proportional hazards regression models were used to assess the associations between serum IGF-1 and incident ischemic stroke after confirming that assumptions of proportional hazards were met. Primary analysis was performed using quintiles of IGF-1 levels. We used 3 models. The first model was adjusted for age and sex. Model 2 was additionally adjusted for systolic blood pressure, smoking, antihypertensive treatment, and prevalent cardiovascular disease. Prior data suggest that glucose intolerance, abdominal obesity, and atrial fibrillation may mediate the association between IGF-1 and risk of stroke,⁴ so we separately adjusted for these covariates in model 3. We also evaluated for the associations between serum IGF-1 and incident ischemic stroke in major subtypes of ischemic stroke (large artery, cardioembolic, and lacunar ischemic stroke). Possible nonlinear associations were evaluated by use of restricted cubic splines. Exploratory analyses were performed using interaction terms to assess effect modification of relations by age, sex, waist-hip ratio (WHR), and diabetes mellitus status and then stratifying analyses by subgroups when significant. These covariates were selected based on biological interest and association with

exposure in our data set. WHR was selected as the preferred metric of body fat content and distribution because it is more strongly correlated with stroke risk than body mass index. Significance was set at $P < 0.05$ for all models and $P < 0.10$ for analyses assessing effect modification. All data were analyzed using SAS version 9.4 (SAS Institute Inc, Cary, NC).

Results

Participant Characteristics

Participant characteristics are provided in Table 1. The mean sample age was 79 years (72–95 years), and 62% participants were women. Participants who did not have IGF-1 levels measured were more likely to be older (Table I in the [online-only Data Supplement](#)). During a mean follow-up period of 10.2 years (0.02–19.28 years), 99 (13%) participants developed ischemic stroke.

IGF-1 and Incident Ischemic Stroke

After adjustment for age and sex, as compared with the fifth (top) quintile, the hazard ratios (and 95% confidence intervals) for ischemic stroke were as follows: first quintile, 2.56 (1.20–5.45); second quintile, 2.12 (0.99–4.54); third quintile, 2.43 (1.17–5.07); fourth quintile, 2.12 (1.00–4.51; Table 2). After adjusting for additional vascular risk factors in model 2, the associations remained significant for the first, 2.35 (1.09–5.06), and third quintile, 2.48 (1.19–5.17), as compared with the fifth (top) quintile (Table 2). In our analysis, we did not find any significant associations between IGF-1 levels and the risk of the main ischemic stroke subtypes separately (Tables II–IV in the [online-only Data Supplement](#)). We found no evidence of nonlinear relationships between IGF-1 levels and the outcomes of interest based on restricted cubic spline analysis. Visual inspection of the splines also suggested relatively linear inverse associations of serum IGF-1 with the incidence of ischemic stroke (Figure II in the [online-only Data Supplement](#)).

Table 1. Baseline Characteristics of Entire Study Sample

N	757
Age, mean \pm SD	79 \pm 5
Female, n (%)	470 (62)
Systolic blood pressure, mean \pm SD	143 \pm 21
Body mass index, mean \pm SD	26.78 \pm 4.68
Waist-hip ratio, mean \pm SD	0.93 \pm 0.09
Current smoking, n (%)	62 (8)
Diabetes mellitus, n (%)	86 (12)
Antihypertensive, n (%)	363 (49)
Prevalent CVD, n (%)	241 (32)
Prevalent AF, n (%)	81 (11)
IGF-1, mean \pm SD	145 \pm 60
Incident stroke, n (%)	119 (16)
Ischemic stroke, n (%)	99 (13)

AF indicates atrial fibrillation; CVD, cardiovascular disease; IGF-1, insulin like growth factor 1; N, number; and SD, standard deviation.

Table 2. Hazard Ratio of Ischemic Stroke Based on IGF-1 Quintiles (N=757, Events=99)

	Quintile of Plasma IGF-1				
	I	II	III	IV	V
Ischemic stroke					
N	151	148	156	150	152
Mean IGF-1 (SD)	69.93 (21.18)	109.8 (10.02)	138.9 (11.69)	170.91 (13.82)	232.97 (41.04)
Age and sex adjusted	2.56 [1.20–5.45]; (0.015)	2.12 [0.99–4.54]; (0.055)	2.43 [1.17–5.07]; (0.018)	2.12 [1.00–4.51]; (0.050)	1.00 (ref)
Multivariate*	2.35 [1.09–5.06]; (0.030)	1.99 [0.93–4.28]; (0.078)	2.48 [1.19–5.17]; (0.016)	2.11 [0.99–4.49]; (0.053)	1.00 (ref)
Multivariate+mediators†	1.86 [0.86–4.01]; (0.113)	1.72 [0.79–3.76]; (0.175)	2.44 [1.17–5.10]; (0.018)	2.15 [1.01–4.60] (0.048)	1.00 (ref)

Results are HR [95% CI] with (*P* values), comparing the top vs bottom IGF-1 quintiles. CI indicates confidence interval; HR, hazard ratio; IGF-1, insulin like growth factor 1; N, number of observations; and SD, standard deviation.

*Adjusted for age, sex, systolic blood pressure, smoking, antihypertensive treatment, and prevalent CVD.

†Additionally adjusted for waist–hip ratio and diabetes mellitus and atrial fibrillation.

Effect Modification by WHR

Our results were suggestive for a potential effect modification by WHR for the association between IGF-1 and incident ischemic stroke ($P=0.083$). In subsequent stratified analysis, quartiles were used to categorize WHR, consistent with prior publications where we have found the highest quartile of the WHR associated with adverse neurological outcomes (mean value for WHR in the top quartile, 1.02). We observed a 41% lower risk of incident ischemic stroke per 1 SD increase in IGF-1 ($P=0.031$) only among subjects who were in the top sex-specific WHR quartile. Additional adjustment with potential confounders (model 2) and mediators (model 3) did not alter these results (Table 3).

Effect Modification by Diabetes Mellitus

We observed evidence for effect modification by diabetes mellitus for the association between IGF-1 and incident ischemic stroke ($P=0.016$). In subsequent stratified analysis, there was a 61% lower risk of incident ischemic stroke ($P=0.007$) per 1 SD increase in IGF-1 only among subjects with diabetes mellitus. Additional adjustment with potential confounders (model 2) and mediators (model 3) did not alter these findings (Table 4).

Table 3. Stratified Analysis by WHR Quartiles Using an Indicator of Top Sex-Specific Quartile

	Top Quartile of WHR	Bottom 3 Quartiles of WHR
Events/N	27/189	71/564
Mean IGF-1 (SD)	144.46 (58.42)	144.57 (60.56)
Multivariate*	0.52 [0.32–0.85]; (0.009)	0.90 [0.69–1.16]; (0.403)
Multivariate+mediators†	0.60 [0.37–0.97]; (0.035)	0.95 [0.74–1.22]; (0.680)

Hazard ratios, HR [95% CI], (*P* values) are estimated for 1 SD (standard deviation) increase in IGF-1 levels in each category. *P* value for interaction =0.083. CI indicates confidence interval; HR, hazard ratio; IS, ischemic stroke; N, number of observations; SD, standard deviation; and WHR, waist–hip ratio.

*Adjusted for age, sex, systolic blood pressure, smoking, antihypertensive treatment, prevalent CVD.

†Additionally adjusted for WHR, diabetes mellitus, and atrial fibrillation.

Discussion

In our prospective community-based cohort of older individuals, circulating IGF-1 levels were associated with risk of ischemic stroke, with subjects in the lowest quintile of IGF-1 levels having a 2.5-fold higher risk of incident ischemic stroke. Associations appeared strongest for diabetic and obese individuals, among whom 1 SD increase in IGF-1 levels (60 ng/mL) was associated with a nearly 60% lower risk of ischemic stroke in people with diabetics and 50% lower risk of ischemic stroke for people in the top WHR quartile. These associations remained significant after adjustment for traditional stroke risk factors. The lack of associations among each ischemic stroke subtypes can be explained by the presence of strong effect modifications and lack of statistical power in each subtype. Our findings suggest that IGF-1 is related to the risk of incident ischemic stroke and support an emerging hypothesis that low circulating IGF-1 may be an especially important determinant of ischemic stroke events in obese and diabetic individuals.

Earlier studies have suggested that IGF-1 may be atherogenic by inducing vascular smooth muscle cell proliferation.

Table 4. Stratified Analysis by Diabetes Mellitus Status Using an Indicator of Top Sex-Specific Quartile

	Diabetes Mellitus	No Diabetes Mellitus
Events/N	11/86	87/655
Mean IGF-1 (SD)	152.08 (66.35)	144.34 (59.22)
Age and sex adjusted	0.39 [0.20–0.78]; (0.007)	0.88 [0.69–1.11]; (0.277)
Multivariate*	0.42 [0.22–0.79]; (0.007)	0.91 [0.72–1.16]; (0.451)
Multivariate+mediators†	0.40 [0.20–0.81]; (0.011)	0.96 [0.77–1.21]; (0.756)

Hazard ratios, HR [95% CI], (*P* values) are estimated for 1 SD (standard deviation) increase in IGF-1 levels in each category. *P* value for interaction =0.016. CI indicates confidence interval; CVD, cardiovascular disease; HR, hazard ratio; IS, ischemic stroke; N, number of observations; and SD, standard deviation.

*Adjusted for age, sex, systolic blood pressure, smoking, antihypertensive treatment, and prevalent CVD.

†Additionally adjusted for waist–hip ratio and atrial fibrillation.

A growing body of evidence indicates, instead, that IGF-1 has protective effects on the vasculature.^{18,19} IGF-1 can directly oppose endothelial dysfunction and development of ischemic stroke through its effects on NO production, plaque stability, anti-inflammatory actions, increased endothelial cell survival, and inhibition of endothelial cell apoptosis¹⁻⁵ and indirectly through an inverse association with traditional cardiovascular disease risk factors.⁵⁻⁷ In vivo human studies have demonstrated that infusion of IGF-1 into human brachial arteries increased blood flow in the forearm by NO-dependent mechanisms.²⁰ Lower circulating IGF-1 levels have been associated with the presence of traditional stroke risk factors, particularly diabetes mellitus^{4,11} and atrial fibrillation.⁹ Hence, the effects of IGF-1 levels on cerebrovascular events may be mediated through components of the metabolic syndrome and pathways of atrial fibrillation. Furthermore, adults with growth hormone deficiency and resulting low circulating IGF-1 levels had considerably higher risk of mortality because of cerebrovascular diseases²¹ and increased intima-media thickness²² that was reversible after growth hormone replacement.²³

Yet, the contribution of serum IGF-1 levels to risk of incident ischemic stroke in the general population is unclear. To date, only 2 prospective observational studies have evaluated serum IGF-1 levels and the risk of incident stroke.^{12,13} In a prospective nested case-control study within a Danish population with 254 cases of incident ischemic stroke, subjects in the bottom quartile of IGF-1 were at increased risk of ischemic stroke (odds ratio, 2.06, 95% confidence interval, 1.05-4.03) when compared with participants in the top quartile.¹² In contrast, among older adults within the CHS (Cardiovascular Health Study), no association was found between total IGF-1 levels and the risk of coronary events or ischemic stroke.¹³ Our epidemiological observations of an inverse association of baseline IGF-1 concentrations with incident ischemic stroke are consistent with previous experimental results. Hence, low IGF-1 may represent an additional independent risk factor for ischemic stroke in insulin-resistant states. While our primary analysis suggested that most of the effect is derived from the difference between top IGF-1 quintile versus the bottom 4 IGF-1 quintiles, there was no evidence of nonlinear relationships between IGF-1 levels and the outcomes of interest based on restricted cubic spline analysis. We were able to demonstrate the presence of a strong effect modification for this association, and therefore, computing and interpreting an overall estimate of association may not be reliable. Although our study was observational, the temporal associations and the consistency of results in multiple stratified analyses could suggest the possibility of a causal association. Reports demonstrating lower values of carotid intima-media thickness and high endothelium-dependent vasodilation in individuals with IGF-1 gene polymorphisms associated with higher levels further support a causal relationship.⁸

Obesity and type 2 diabetes mellitus are characterized by insulin resistance, reduced NO availability, and increased risk of atherothrombosis. Clinical trials have shown that intensive glycemic control does not reduce the risk of macrovascular events and stroke in type 2 diabetes mellitus, suggesting that

factors beyond blood glucose mediated vascular risk in these individuals.^{24,25} IGF-1, like insulin, protects vascular integrity mainly through activation of NO synthase via an Akt-catalyzed phosphorylation.^{26,27} IGF-1, also, enhances insulin sensitivity and improves glycemic control, lipid profile, and body composition in individuals with type 2 diabetes mellitus.²⁸ However, recent animal studies demonstrated that IGF-1-induced NO availability is blunted in diabetic and obese mice.^{29,30} An association between a decline in NO availability and accelerated atherosclerosis is also well established, particularly, in those with obesity and type 2 diabetes mellitus.^{31,32} In fact, insulin resistance triggers atherothrombosis mainly through impaired NO activation and an imbalance between NO availability and accumulation of reactive oxygen species, leading to endothelial dysfunction.³³ Also, impaired NO synthesis is implicated in the pathogenesis of atrial fibrillation.³⁴ In an experimental study by Cai et al,³⁵ authors concluded that loss of left atrial NO activity contributes to the thromboembolic events associated with atrial fibrillation. Taken together, these experimental and clinical findings suggest that low IGF-1 levels could have detrimental effects on the vasculature, especially in individuals with type 2 diabetes mellitus or obesity. Our observation of a substantially lower risk of incident stroke in diabetic and centrally obese individuals with higher serum IGF-1 is consistent with these studies. If our findings are replicated by others, serum IGF-1 levels may serve as an important marker in ischemic stroke risk assessment, particularly in individuals with type 2 diabetes mellitus or central obesity. New mechanism-based therapies that improve endothelial dysfunction are required to prevent macrovascular events and stroke in these individuals, targeting both hyperglycemia and insulin-resistance pathways and simultaneously improving metabolic and vascular functions.

Our investigation had strengths. Incident stroke was prospectively adjudicated using a consistent set of criteria and based on continuous surveillance of all subjects. Furthermore, covariates were assessed comprehensively prior to events. This is a well-established community-based cohort with negligible loss to follow-up.

Our study also had limitations. We did not measure biologically active free IGF-1 and IGF-binding proteins. It is suggested that levels of IGF-binding proteins may affect the actions of circulating IGF-1 on cardiovascular risk.²⁰ Yet, circulating IGF-1 is highly correlated with the ratio of IGF-1 to IGF-binding proteins,³⁶ and therefore, measuring circulating IGF-1 alone may have led to an underestimation of true relationships with incident stroke. IGF-1 levels were measured at baseline, and metabolic fluctuations could have increased exposure misclassification over time. This cohort included older European Americans that may limit generalizability to other ethnicities or younger populations. The observational design cannot exclude residual confounding by unknown or unmeasured factors. Yet, results were robust to adjustment for multiple major risk factors. Finally, it should be noted that the precision of our risk estimates in the stratified analysis was moderate because of the relatively small number of events in subgroups as suggested by

the relatively wide confidence intervals and may lead to over-estimation of effect estimates.

Summary

Our findings suggest that circulating IGF-1 levels are linked to lower risk of incident ischemic stroke among adults later in life, with potentially highest impact in individuals with type 2 diabetes mellitus or central obesity. These findings suggest the hypothesis that IGF-1 is involved in the pathogenesis of ischemic stroke, particularly in the insulin-resistant states. Further studies are warranted to explore the underlying cellular mechanisms and investigate potential clinical implications.

Sources of Funding

This study was supported by the Framingham Heart Study's National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) contract (N01 HC25195 and N01 HHSN-268201500001) and by grants from the National Institute of Neurological Disorders and Stroke (NINDS; R01 NS017950), the National Institute on Aging (R01 AG16495, AG 033040, AG008122, AG033193, AG031287, and K23 AG038444), and the American Heart Association (11CRP4930020).

Disclosures

Dr Roubenoff is a full-time employee of Novartis Institutes for Biomedical Research. The other authors report no conflicts.

References

- Hutter R, Sauter BV, Reis ED, Roque M, Vorchheimer D, Carrick FE, et al. Decreased reendothelialization and increased neointima formation with endostatin overexpression in a mouse model of arterial injury. *Circulation*. 2003;107:1658–1663. doi: 10.1161/01.CIR.0000058169.21850.CE.
- Spies M, Nestic O, Barrow RE, Perez-Polo JR, Herndon DN. Liposomal IGF-1 gene transfer modulates pro- and anti-inflammatory cytokine mRNA expression in the burn wound. *Gene Ther*. 2001;8:1409–1415. doi: 10.1038/sj.gt.3301543.
- Schini-Kerth VB. Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. *J Endocrinol Invest*. 1999;22(5 suppl):82–88.
- Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. *Lancet*. 2002;359:1740–1745. doi: 10.1016/S0140-6736(02)08655-5.
- Gillespie CM, Merkel AL, Martin AA. Effects of insulin-like growth factor-I and LR3IGF-I on regional blood flow in normal rats. *J Endocrinol*. 1997;155:351–358.
- Haylor J, Singh I, el Nahas AM. Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I. *Kidney Int*. 1991;39:333–335.
- Galderisi M, Caso P, Cicala S, De Simone L, Barbieri M, Vitale G, et al. Positive association between circulating free insulin-like growth factor-I levels and coronary flow reserve in arterial systemic hypertension. *Am J Hypertens*. 2002;15:766–772.
- Sesti G, Mannino GC, Andreozzi F, Greco A, Perticone M, Sciacqua A, et al. A polymorphism at IGF1 locus is associated with carotid intima media thickness and endothelium-dependent vasodilatation. *Atherosclerosis*. 2014;232:25–30. doi: 10.1016/j.atherosclerosis.2013.10.024.
- Duron E, Vidal JS, Funalot B, Brunel N, Viollet C, Seux ML, et al. Insulin-like growth factor I, insulin-like growth factor binding protein 3, and atrial fibrillation in the elderly. *J Gerontol A Biol Sci Med Sci*. 2014;69:1025–1032. doi: 10.1093/gerona/glt206.
- Berryman DE, Glad CA, List EO, Johannsson G. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. *Nat Rev Endocrinol*. 2013;9:346–356. doi: 10.1038/nrendo.2013.64.

- Perticone F, Sciacqua A, Tassone EJ, Miceli S, Maio R, Addesi D, et al. One-hour post-load plasma glucose and IGF-1 in hypertensive patients. *Eur J Clin Invest*. 2012;42:1325–1331. doi: 10.1111/eci.12005.
- Johnsen SP, Hundborg HH, Sørensen HT, Orskov H, Tjønneland A, Overvad K, et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. *J Clin Endocrinol Metab*. 2005;90:5937–5941. doi: 10.1210/jc.2004-2088.
- Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, Rohan TE, et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. *J Clin Endocrinol Metab*. 2007;92:1319–1325. doi: 10.1210/jc.2006-1631.
- Kawachi S, Takeda N, Sasaki A, Kokubo Y, Takami K, Sarui H, et al. Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2005;25:617–621. doi: 10.1161/01.ATV.0000154486.03017.35.
- Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. *Am J Public Health Nations Health*. 1951;41:279–281.
- Hintz RL, Liu F, Chang D, Seegan G. A sensitive radioimmunoassay for somatomedin-C/insulin-like growth-factor I based on synthetic insulin-like growth factor 57-70. *Horm Metab Res*. 1988;20:344–347. doi: 10.1055/s-2007-1010832.
- Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. *Stroke*. 1991;22:312–318.
- Conti E, Carrozza C, Capoluongo E, Volpe M, Crea F, Zuppi C, et al. Insulin-like growth factor-1 as a vascular protective factor. *Circulation*. 2004;110:2260–2265. doi: 10.1161/01.CIR.0000144309.87183.FB.
- Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. *Arterioscler Thromb Vasc Biol*. 1998;18:277–282.
- Chisalita SI, Arqvist HJ. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells. *Am J Physiol Endocrinol Metab*. 2004;286:E896–E901. doi: 10.1152/ajpendo.00327.2003.
- Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. *Clin Endocrinol (Oxf)*. 1997;46:75–81.
- Colao A, Di Somma C, Filippella M, Rota F, Pivonello R, Orio F, et al. Insulin-like growth factor-1 deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency. *Clin Endocrinol (Oxf)*. 2004;61:360–366. doi: 10.1111/j.1365-2265.2004.02105.x.
- Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. *J Clin Endocrinol Metab*. 1999;84:453–457. doi: 10.1210/jcem.84.2.5456.
- Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. *BMJ*. 2011;343:d4169.
- Goodarzi MO, Psaty BM. Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point? *JAMA*. 2008;300:2051–2053. doi: 10.1001/jama.2008.510.
- Li G, Barrett EJ, Wang H, Chai W, Liu Z. Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. *Endocrinology*. 2005;146:4690–4696. doi: 10.1210/en.2005-0505.
- Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. *J Clin Invest*. 1996;98:894–898. doi: 10.1172/JCI118871.
- Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. *Diabetes*. 1996;45:91–100.
- Noronha BT, Li JM, Wheatcroft SB, Shah AM, Kearney MT. Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. *Diabetes*. 2005;54:1082–1089.

30. Imrie H, Abbas A, Viswambharan H, Rajwani A, Cubbon RM, Gage M, et al. Vascular insulin-like growth factor-I resistance and diet-induced obesity. *Endocrinology*. 2009;150:4575–4582. doi: 10.1210/en.2008-1641.
31. Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. *Diabet Med*. 2003;20:255–268.
32. Williams IL, Chowienczyk PJ, Wheatcroft SB, Patel AG, Sherwood RA, Momin A, et al. Endothelial function and weight loss in obese humans. *Obes Surg*. 2005;15:1055–1060. doi: 10.1381/0960892054621134.
33. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. *Circ Res*. 2001;88:E14–E22.
34. Bonilla IM, Sridhar A, Györke S, Cardounel AJ, Carnes CA. Nitric oxide synthases and atrial fibrillation. *Front Physiol*. 2012;3:105. doi: 10.3389/fphys.2012.00105.
35. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. *Circulation*. 2002;106:2854–2858.
36. Benbassat CA, Maki KC, Unterman TG. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures. *J Clin Endocrinol Metab*. 1997;82:1484–1491. doi: 10.1210/jcem.82.5.3930.

Serum Insulin-Like Growth Factor 1 and the Risk of Ischemic Stroke: The Framingham Study

Hamidreza Saber, Jayandra J. Himali, Alexa S. Beiser, Ashkan Shoamanesh, Aleksandra Pikula, Ronenn Roubenoff, Jose R. Romero, Carlos S. Kase, Ramachandran S. Vasani and Sudha Seshadri

Stroke. 2017;48:1760-1765; originally published online June 8, 2017;

doi: 10.1161/STROKEAHA.116.016563

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2017 American Heart Association, Inc. All rights reserved.

Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://stroke.ahajournals.org/content/48/7/1760>

Data Supplement (unedited) at:

<http://stroke.ahajournals.org/content/suppl/2017/06/12/STROKEAHA.116.016563.DC1>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Stroke* is online at:
<http://stroke.ahajournals.org/subscriptions/>

SUPPLEMENTAL MATERIAL

Supplemental Table I. Baseline Characteristics of those enrolled and those not in the study sample.

	IGF-1 Measurements Available	No IGF-1 Measurements Available	
	N=757	N=320	p-value
Age, mean ± SD	79±5	84±7	<0.001
Female, n (%)	470 (62)	201 (71)	0.004
Body Mass Index, mean ± SD	26.50 [23.51, 29.35] *	25.53 [22.83, 29.46] *	0.409
Waist-Hip Ratio, mean ± SD	0.93±0.09	0.91±0.09	0.088
Current Smoking, n (%)	62 (8)	25 (9)	0.693
Anti-hypertensive, n (%)	363 (51)	140 (54)	0.420
Prevalent AF, n (%)	81 (11)	39 (14)	0.149
IGF-1, mean ± SD	145±60		
Incident Stroke, n (%)	119 (16)		
Ischemic Stroke, n (%)	99 (13)		

N: Number; CVD: Cardiovascular disease; IGF-1: Insulin like growth factor1, SD: Standard Deviation, AF: Atrial Fibrillation.

*Median [Q1, Q3] .The comparison of means was performed on the natural log transformation of BMI.

Supplemental Table II. Stratified analysis by ischemic stroke subtypes.

Ischemic Stroke subtype	Large artery disease	Lacunar	Cardioembolic
Age and sex adjusted*	0.87 [0.61, 1.23] (0.42)	0.84 [0.46, 1.51] (0.54)	0.73 [0.52, 1.01] (0.06)
Multivariate †	0.92 [0.64, 1.31] (0.64)	0.83 [0.46, 1.51] (0.53)	0.73 [0.52, 1.02] (0.06)
Multivariate+Mediators‡	0.92 [0.64, 1.31] (0.91)	0.94 [0.51, 1.72] (0.82)	0.75 [0.54, 1.05] (0.09)

Hazard ratios, HR [95% CI], (p-values) are estimated for 1 SD (standard deviation) increase in IGF-1 levels in each category.

HR: Hazard ratio; CI: Confidence interval.

†: Adjusted for age, sex, systolic blood pressure, smoking, anti-hypertensive treatment, prevalent CVD.

‡: Additionally adjusted for Waist-hip ratio and diabetes mellitus.

Supplemental table III. Hazard ratio of cardioembolic ischemic stroke based on IGF-1 quintiles (N=757, Events=46)

	Quintile of Plasma IGF-1				
	I	II	III	IV	V
N	151	148	156	150	152
Age and sex adjusted*	2.91 [1.01, 8.41] (0.048)	2.45 [0.85, 7.09] (0.099)	2.40 [0.84, 6.82] (0.101)	1.23 [0.38, 4.03] (0.732)	1.00 (ref)
Multivariate †	2.82 [0.96, 8.28] (0.059)	2.36 [0.82, 6.86] (0.114)	2.41 [0.85, 6.87] (0.099)	1.15 [0.35, 3.79] (0.813)	1.00 (ref)
Multivariate+Mediators+AF ‡	1.67 [0.57, 4.94] (0.352)	1.93 [0.65, 5.73] (0.235)	2.32 [0.80, 6.70] (0.121)	1.08 [0.33, 3.59] (0.895)	1.00 (ref)

Results are HR [95% CI] with (p-values), comparing the top vs. bottom IGF-1 quintiles.

HR: Hazard ratio; CI: Confidence interval; SD: Standard deviation; N: Number of observations.

†: Adjusted for age, sex, systolic blood pressure, smoking, anti-hypertensive treatment and prevalent CVD

‡: Additionally adjusted for waist-hip ratio, diabetes mellitus, and prevalent AF.

Supplemental table IV. Hazard ratio of non-cardioembolic ischemic stroke based on IGF-1 quintiles (N=757, Events=53)

	Quintile of Plasma IGF-1				
	I	II	III	IV	V
N	151	148	156	150	152
Age and sex adjusted*	2.26 [0.77, 6.65] (0.138)	1.82 [0.61, 5.47] (0.285)	2.46 [0.88, 6.92] (0.088)	3.00 [1.09, 8.26] (0.034)	1.00 (ref)
Multivariate †	1.99 [0.66, 5.96] (0.221)	1.67 [0.55, 5.04] (0.363)	2.52 [0.89, 7.10] (0.081)	3.15 [1.14, 8.74] (0.027)	1.00 (ref)
Multivariate+Mediators+AF ‡‡	1.89 [0.63, 5.69] (0.260)	1.44 [0.46, 4.45] (0.530)	2.53 [0.90, 7.12] (0.080)	3.40 [1.22, 9.46] (0.019)	1.00 (ref)

Results are HR [95% CI] with (p-values), comparing the top vs. bottom IGF-1 quintiles.

HR: Hazard ratio; CI: Confidence interval; SD: Standard deviation; N: Number of observations.

†: Adjusted for age, sex, systolic blood pressure, smoking, anti-hypertensive treatment and prevalent CVD

‡: Additionally adjusted for waist-hip ratio, diabetes mellitus, and prevalent AF.




Figure legend for supplemental figure.

Supplemental Figure I. Study sample flow chart.




Figure legend for supplemental figure.

Supplemental Figure II. Multivariable-adjusted relationship of serum IGF-1 levels with incident ischemic stroke evaluated by use of restricted cubic splines with 3 knots at fixed percentiles (5 th, 50 th and 95th) of distribution. Hazard ratios (red solid line) and 95% CIs (black dotted lines)

were estimated using restricted cubic spline Cox regression analysis. The multivariable model was adjusted for age, sex, systolic blood pressure, current smoking status, treatment for hypertension and prevalent CVD.

s_s_igf1: sex specific IGF-1; RCS: Restricted cubic spline; CL: confidence limit; HR: hazard ratio.